Clinical Trials

A Study of PRT1419 in Patients With Advanced Solid Tumors

NCT04837677

Description of the Study

This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1) inhibitor, in patients with advanced solid tumors. The purpose of this study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal biological dose to be used in subsequent development of PRT1419.

Eligibility: